Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.69 |
| ▸ | DRD3 | P35462 | 3/20 | 0.69 |
| ▸ | HTR1A | P08908 | 5/20 | 0.67 |
| ▸ | HTR7 | P34969 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532577 | 0.96 | HTR1A (0.64) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL10631261 | 0.91 | HTR1A (0.58) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL13532574 | 0.87 | HTR1A (0.58) | DRD2HTR1AHTR7MEN1KMT2A | |
| SCHEMBL20048037 | 0.86 | SMN1; SMN2 (0.56) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL13532573 | 0.86 | KDM4E (0.64) | DRD2DRD3HTR1AHTR7HTR2A | |
| SCHEMBL10414460 | 0.83 | DRD2 (1.00) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL13875119 | 0.82 | HTR1A (1.00) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL6244716 | 0.81 | DRD2 (0.72) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL16281735 | 0.81 | HTR1A (0.97) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL16281719 | 0.81 | HTR1A (0.97) | DRD2DRD3HTR1AHTR7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137854-A1 | TAAR Receptor Agonists for the Treatment of Alopecia | JUPITER WELLNESS INC. | 2021-05-13 | — | — | US | claimed |
| EP-3154967-B1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | JOHNSON MATTHEY PLC (GB) | 2020-07-29 | — | — | EP | claimed |
| WO-2020023084-A1 | TAAR RECEPTOR AGONISTS FOR THE TREATMENT OF ALOPECIA | APPLIED BIOLOGY, INC. (US) | 2020-01-30 | — | — | WO | claimed |
| US-20190091164-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same | PFIZER INC. (US) | 2019-03-28 | — | — | US | claimed |
| CN-108348506-A | Include the therapeutic nanoparticle and its preparation and application of therapeutic agent | 辉瑞公司 | 2018-07-31 | — | — | CN | claimed |
| EP-3337516-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2018-06-27 | — | — | EP | claimed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | claimed |
| EP-3154967-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | Johnson Matthey Public Limited Company (GB) | 2017-04-19 | — | — | EP | claimed |
| WO-2017034991-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2017-03-02 | — | — | WO | claimed |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-23 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1946404-A | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | CN | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20040023948-A1 | Fast-dispersing dosage form containing 5-HT1 agonists | CATALENT USA PAINTBALL, INC. | 2004-02-05 | — | — | US | claimed |
| EP-0969842-A1 | PHARMACEUTICAL COMPOSITION | R.P. Scherer Limited (GB) | 2000-01-12 | — | — | EP | claimed |
| WO-1998042344-A1 | PHARMACEUTICAL COMPOSITION | R. P. SCHERER LIMITED (GB) | 1998-10-01 | — | — | WO | claimed |
| US-4771044-A | ANTIPSYCHOTICS, ANTIDEPRESSANTS AND ANXIOLYTICS | KALI-CHEMIE PHARMA GMBH (DE) | 1988-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | DRD2 110/4885DRD3 93/4885HTR1A 270/4885 |
| US-20190091164-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same | CTSA, GAA, EEA1 | DRD2 4865/4885DRD3 4839/4885HTR1A 4649/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | DRD2 38/4885DRD3 164/4885HTR1A 222/4885 |
| US-20170049709-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CTSA, GAA, EEA1 | DRD2 4865/4885DRD3 4839/4885HTR1A 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.